To date, even for recently defined CNS WHO grade 4 subtypes of diffuse gliomas other than GB, which are more prevalent in younger patients (for example, H3G34-mutant diffuse hemispheric gliomas or IDH-mutant grade 4 astrocytoma), the therapeutic strategies remain similar for all of them [5]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).